Antiviral therapies for chronic hepatitis C virus infection with cirrhosis

Table 3 Sustained virological response rates for cirrhotic patients who were treated with interferon-free regimens

Ref. (name of trial)	Regimen; genotypes; No. of patients (n)	Patient characteristics	SVR rates: cirrhosis
			vs non-cirrhosis
Kumada et al[27] (AI447026)	ASV + DCV; G1; n = 222	IFN-intolerant/IFN-ineligible	91% vs 87%
		IFN-non-response1	91% vs 79%
Manns et al[28] (HALLMARK-DUAL)	ASV + DCV; G1; n = 645	Treatment naïve	91% vs 89%3
		IFN-non-response1	87% vs 80%
		IFN-intolerant/IFN-ineligible	79% vs 84%
Lawitz et al[32] (LONESTAR)	SOF + LDV ± RBV; G1; n = 40	Treatment experienced2	91% vs 100%34
			100% vs 100%5
Osinusi et al[29]	SOF + RBV; G1; n = 50	Treatment naïve	38% vs 65%6
Lawitz et al[26] (FISSION)	SOF + RBV; G2-3; n = 256	Treatment naïve; 12-wk regimen	G2; 83% vs 97%3
			G3; 34% vs 61%3
Jacobson et al[30] (POSITRON, FUSION)	SOF + RBV; G2-3; n = 408	IFN-ineligible/IFN-intolerant	G2; 94% vs 92%3
		(POSITRON); 12-wk regimen	G3; 21% vs 68%3
		IFN-failure7 (FUSION)
		12-wk regimen	G2; 60% vs 96% (90%)
			G3; 19% vs 37%
		16-wk regimen	G2; 78% vs 100% (92%)
			G3; 61% vs 63%
Zeuzem et al[31] (VALENCE)	SOF + RBV; G2-3; n = 323	Treatment-naïve
		12-wk regimen	G2; 100% vs 97%3
		24-wk regimen	G3; 92% vs 93%3
		Treatment-experienced
		12-wk regimen	G2; 88% vs 91%
		24-wk regimen	G3; 60% vs 85%
Lawitz et al[35] (COSMOS)	SMV + SOF ± RBV for 12 or 24 wk; G1; n = 167	F0-2; non-responders	F0-2; 90%3
		F3-4; non-responders or naive	F3-4; 94%
Poordad et al[36] (TURQUOISE-II)	Paritaprevir, ritonavir, ombitasvir	Treatment-naïve	94%38
	+ dasabuvir + RBV 12 or 24 wk; G1; n = 380	Treatment-experienced
		Relapse	98%
		Partial response	96%
		Null response	91%

¹Null or partial response during previous treatment;

²Patients experienced triple therapy including telaprevir or boceprevir;

³Data for SVR12;

⁴SVR rates for ribavirin-containing regimens;

⁵SVR rates for regimens without ribavirin;

⁶Comparison between F3-4 and F0-1 (Knodell score);

⁷Relapse, null or partial response to previous treatment;

⁸All patients included in the study had cirrhosis. ASV: Asunaprevir; DCV: Daclatasvir; G: Genotype; IFN: Interferon; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir; SVR: Sustained virological response; SMV: Simeprevir.